Keros Therapeutics Reports Recent Business Highlights and First Quarter 2021 Financial Results
May 06, 2021 16:01 ET
|
Keros Therapeutics, Inc.
LEXINGTON, Mass., May 06, 2021 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery,...
Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2020 Financial Results
March 25, 2021 08:00 ET
|
Keros Therapeutics, Inc.
LEXINGTON, Mass., March 25, 2021 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery,...
Keros Therapeutics Presents Results from Preclinical Studies of KER-050 and ALK2 Inhibitors at the European School of Haematology (ESH) 2nd Translational Research E-Conference
March 05, 2021 08:00 ET
|
Keros Therapeutics, Inc.
LEXINGTON, Mass., March 05, 2021 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery,...
Keros Therapeutics to Present at the H.C. Wainwright Global Life Sciences 2021 Virtual Conference
March 02, 2021 08:00 ET
|
Keros Therapeutics, Inc.
LEXINGTON, Mass., March 02, 2021 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and...
Keros Therapeutics to Present at the 10th Annual SVB Leerink Global Healthcare Conference
February 17, 2021 08:00 ET
|
Keros Therapeutics, Inc.
LEXINGTON, Mass., Feb. 17, 2021 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and...
Keros Therapeutics Announces Addition to NASDAQ Biotechnology Index
December 21, 2020 08:00 ET
|
Keros Therapeutics, Inc.
LEXINGTON, Mass., Dec. 21, 2020 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and...
Keros Therapeutics Appoints Mary Ann Gray, Ph.D., to its Board of Directors
December 17, 2020 08:00 ET
|
Keros Therapeutics, Inc.
LEXINGTON, Mass., Dec. 17, 2020 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery,...
Keros Therapeutics Presents Clinical Trial and Preclinical Study Results from its ALK2 Inhibitor Program, Including KER-047 Phase 1 Data, and KER-050 Preclinical Data, at the Virtual 62nd American Society of Hematology Annual Meeting and Exposition
December 07, 2020 08:00 ET
|
Keros Therapeutics, Inc.
Presentation highlights data from Keros’ Phase 1 clinical trial of KER-047, which demonstrated robust and sustained dose-related increases in serum iron and transferrin saturation that were associated...
Keros Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
November 17, 2020 16:01 ET
|
Keros Therapeutics, Inc.
LEXINGTON, Mass., Nov. 17, 2020 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and...
Keros Therapeutics to Present at the Jefferies Virtual London Healthcare Conference
November 16, 2020 08:00 ET
|
Keros Therapeutics, Inc.
LEXINGTON, Mass., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and...